EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TaiMed Biologics's Enterprise Value is NT$17,536.2 Mil.
TaiMed Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$168.4 Mil. Therefore, TaiMed Biologics's EV-to-FCF for today is 104.15.
The historical rank and industry rank for TaiMed Biologics's EV-to-FCF or its related term are showing as below:
ROCO:4147'
s EV-to-FCF Range Over the Past 10 Years
Min: -871.7 Med: -39.81 Max: 277.03
Current: 104.95
During the past 13 years, the highest EV-to-FCF of TaiMed Biologics was 277.03. The lowest was -871.70. And the median was -39.81.
ROCO:4147's EV-to-FCF is ranked worse than 89.39% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs ROCO:4147: 104.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TaiMed Biologics (ROCO:4147) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TaiMed Biologics's PE Ratio (TTM) for today is calculated as:
TaiMed Biologics's share price for today is NT$69.50.
TaiMed Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TaiMed Biologics EV-to-FCF Related Terms
TaiMed Biologics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, TaiMed Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's EV-to-FCF falls into.
TaiMed Biologics's current Enterprise Value is NT$17,536.2 Mil.
TaiMed Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$168.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a EV-to-FCF of 104.15 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #295 out of 330 companies in the Biotechnology industry, placing it in the top 89.4%.
Is TaiMed Biologics' EV-to-FCF too high?
TaiMed Biologics' current EV-to-FCF is 104.15. The Biotechnology industry median EV-to-FCF is 16.36. TaiMed Biologics' value of 104.15 is 536.6% above this industry median. Based on the distribution chart, TaiMed Biologics ranks #295 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #295 out of 330 companies for EV-to-FCF. This places TaiMed Biologics in the lower half of its industry. The industry median EV-to-FCF is 16.36. TaiMed Biologics' value of 104.15 is 536.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current EV-to-FCF of 104.15 is 536.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current EV-to-FCF is 104.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current EV-to-FCF is 104.15 and 536.6% above the Biotechnology industry median of 16.36. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current EV-to-FCF is 104.15 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
EV-to-FCF: 104.15
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
Industry Position: 536.6% above the Biotechnology median (#295 of 330)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
